• Another class of AMPK regulator is peptidyl prolyl cis trans

  2024-04-03

  

  Another class of AMPK regulator is peptidyl-prolyl cis/trans isomerase (PPIase) NIMA-interacting 1 (Pin1), which binds to a number of proteins and regulates oncogenesis and metabolic diseases (Khanal et al., 2013; Zhou and Lu, 2016). Pin1 has been shown to bind to and inhibit AMPK; therefore, at lea

• The disease stimulatory effects of

  2024-04-02

  

  The disease-stimulatory effects of hyperadiponectinemia in patients contradict a previous view based on studies of preclinical models showing that APN might be beneficial for AD [8]. Indeed, despite the action of APN as a risk factor in patients with AD, APN is protective against oxidative stress-in

• The potential use of derivatives belonging to

  2024-04-02

  

  The potential use of derivatives belonging to this series as therapeutic agents mostly depends on their pharmacokinetics and pharmacodynamics. The pharmacokinetic phase includes absorption, distribution, metabolism and excretion (ADME) of the studied compounds. Therefore, preliminary data for theore

• br Acknowledgement br Introduction There has been great

  2024-04-02

  

  Acknowledgement Introduction There has been great progress in the treatment of autoimmune disease during the past several decades. However, the majority of autoimmune diseases have no known cure. B lymphocytes and autoantibodies play important roles in many autoimmune diseases, including rheum

• br The future of cancer therapeutics with Aurora kinase inhi

  2024-04-02

  

  The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor AGK 2 synthesis suggest

• br The future of cancer therapeutics with Aurora kinase inhi

  2024-04-02

  

  The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor casr suggests that thes

• br Colorectal carcinoma The growth

  2024-04-02

  

  Colorectal carcinoma The growth rate of murine colon adenocarcinoma tumors decreased upon inhibition of 5-LOX, an enzyme that harbors counteracting properties to 15-LOX [28]. It is not clear whether 15-LOX was associated with this phenomenon, but its expression is induced in the colon carcinoma c

• While increased arginase levels has been shown in animal

  2024-04-02

  

  While increased arginase levels has been shown in animal models and in humans with cardiovascular dysfunction [16], [22], [23], it is unknown whether plasma levels or activity of Arginase may predict ED risk. In addition, recent evidence suggests that plasma l-arginine hydrolysis by arginases limits

• Introduction AMP activated protein kinase AMPK is mainly kno

  2024-04-01

  

  Introduction AMP-activated protein kinase (AMPK) is mainly known as a highly conserved and ubiquitously expressed energy sensor that is highly sensitive to changes in cellular energy levels (by sensing increases in AMP:ATP and ADP:ATP ratios) and makes appropriate adjustment to balance the consumpt

• This suggestion was confirmed by immunohistochemical studies

  2024-04-01

  

  This suggestion was confirmed by immunohistochemical studies in which the immunoreactivity of the enzyme was actually higher at the earlier rather than at the advanced stages of the disease. Importantly, a later study showed that the biochemical signature of 12/15LO enzymatic activation (i.e., 12-HE

• It is noteworthy to mention the

  2024-04-01

  

  It is noteworthy to mention the limitations of this study like tPA plus LB1 treatment beyond 4 h after stroke was not investigated. Especially 6 or 8 h after stroke could be studied in future projects for translational purposes. Second drawback might be that we performed the experiments in different

• br Results br Discussion Many tumor cells rely on

  2024-04-01

  

  Results Discussion Many tumor Bicalutamide rely on EAAs to provide fundamental building blocks for macromolecular biosynthesis because they cannot synthesize EAAs de novo (Hattori et al., 2017; Sheen et al., 2011). Therefore, they must use highly effective transporters to maximize EAA uptake f

• br Development of lorlatinib from crizotinib

  2024-04-01

  

  Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes

• br Conflict of interest statement br Acknowledgements

  2024-04-01

  

  Conflict of interest statement Acknowledgements We are very grateful to Maura Agate for her excellent editorial assistance. The work reported in this article was supported largely by the Italian MIUR. Introduction Atenolol is a selective β1-adrenergic receptor blocker that is orally effect

• Since non lipoprotein derived free cholesterol

  2024-04-01

  

  Since non-lipoprotein-derived free cholesterol is recycled from the plasma membrane through the endosomal system through receptor-independent mechanisms, we wanted to determine whether ABCA2 could alter the trafficking of this source of free cholesterol. Our approach was to measure the effect of mob

15552 records 177/1037 page Previous Next First page 上5页 176177178179180 下5页 Last page